LON:DOCS Dr. Martens (DOCS) Share Price, News & Analysis GBX 69.60 +1.80 (+2.65%) As of 05/22/2026 12:07 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Dr. Martens Stock (LON:DOCS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dr. Martens alerts:Sign Up Key Stats Today's Range 67.94▼ 71.1050-Day Range 60.70▼ 69.9052-Week Range 53.05▼ 100.87Volume1.48 million shsAverage Volume9.73 million shsMarket Capitalization£673.17 millionP/E Ratio40.94Dividend Yield3.76%Price TargetGBX 110Consensus RatingModerate Buy Company Overview Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Our product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories. Read More Dr. Martens Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreDOCS MarketRank™: Dr. Martens scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingDr. Martens has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialDr. Martens has a consensus price target of GBX 110, representing about 58.0% upside from its current price of GBX 69.60.Amount of Analyst CoverageDr. Martens has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Martens' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Martens is 40.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Martens is 40.94, which means that it is trading at a less expensive P/E ratio than the Consumer Cyclical sector average P/E ratio of about 77.72.Price to Earnings Growth RatioDr. Martens has a PEG Ratio of 6.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Martens has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DOCS. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipDr. Martens is a leading dividend payer. It pays a dividend yield of 3.76%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthDr. Martens does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Martens is 150.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Dr. Martens' dividend. News and Social Media3.1 / 5News Sentiment1.01 News SentimentDr. Martens has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Consumer Cyclical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Dr. Martens this week, compared to 2 articles on an average week.Search InterestOnly 24 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Company Ownership2.6 / 5Insider TradingSelling Shares Cluster Insider Buying2 insiders have purchased shares of Dr. Martens in the last three months. Multiple insiders buying is a strong bullish signal.Insider Buying vs. Insider SellingIn the past three months, Dr. Martens insiders have sold 22,351.60% more of their company's stock than they have bought. Specifically, they have bought £599.84 in company stock and sold £134,673.66 in company stock.Percentage Held by Insiders2.81% of the stock of Dr. Martens is held by insiders.Percentage Held by Institutions32.17% of the stock of Dr. Martens is held by institutions.Read more about Dr. Martens' insider trading history. Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Martens and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DOCS Stock News HeadlinesDr. Martens DOCS fiscal year 2026 earnings return to profit growthMay 19, 2026 | msn.comAs Dr Martens bounces back to profit growth, is it time to buy the shares?May 19, 2026 | msn.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 23 at 1:00 AM | Brownstone Research (Ad)Dr Martens stomps higher as strategy tweak boosts profits - UPDATEMay 19, 2026 | uk.finance.yahoo.comDr Martens' turnaround gathers pace as annual profit jumps 61%May 19, 2026 | reuters.comDr. Martens Shifts to Consumer-First Strategy as Profit Climbs 61% (DOCS)May 19, 2026 | uk.finance.yahoo.comDr. Martens Plans Share Purchases for Employee Benefit TrustMay 19, 2026 | tipranks.comDr. Martens (LON:DOCS) Insider Acquires £149.12 in StockMay 15, 2026 | insidertrades.comSee More Headlines DOCS Stock Analysis - Frequently Asked Questions How have DOCS shares performed this year? Dr. Martens' stock was trading at GBX 76.60 on January 1st, 2026. Since then, DOCS shares have decreased by 9.1% and is now trading at GBX 69.60. How were Dr. Martens' earnings last quarter? Dr. Martens plc (LON:DOCS) posted its quarterly earnings results on Tuesday, May, 19th. The company reported $4.20 earnings per share for the quarter. The business had revenue of $764.90 million for the quarter. Dr. Martens had a trailing twelve-month return on equity of 6.89% and a net margin of 3.11%. Read the conference call transcript. How do I buy shares of Dr. Martens? Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Dr. Martens own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Martens investors own include boohoo group (BOO), Aston Martin Lagonda Global (AML), ASOS (ASC), Vodafone Group Public (VOD), JD Sports Fashion (JD), Legal & General Group (LGEN) and Lloyds Banking Group (LLOY). Company Calendar Last Earnings5/19/2026Today5/23/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorConsumer Cyclical Industry Footwear & Accessories Sub-IndustryComputer Software Current SymbolLON:DOCS CIKN/A Webwww.drmartensplc.com Phone44 12 1415 7047FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Price Target for Dr. MartensGBX 110 High Price TargetGBX 110 Low Price TargetGBX 110 Potential Upside/Downside+58.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)GBX 1.70 Trailing P/E Ratio40.94 Forward P/E Ratio26.97 P/E Growth6.4Net Income£68.97 million Net Margins3.11% Pretax MarginN/A Return on Equity6.89% Return on Assets8.12% Debt Debt-to-Equity Ratio108.27 Current Ratio2.61 Quick Ratio1.13 Sales & Book Value Annual Sales£764.90 million Price / Sales0.88 Cash FlowGBX 4.87 per share Price / Cash Flow14.29 Book ValueGBX 37.80 per share Price / Book1.84Miscellaneous Outstanding Shares967,193,000Free FloatN/AMarket Cap£673.17 million OptionableNot Optionable Beta0.22 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (LON:DOCS) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Martens plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Martens With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
